What is it about?
The thyroid hormon T3 regulates heart metabolism. In patients with heart failure, T3 levels are low. Among 278 eligible patients with heairt failure and low T3, thirteen patients completed the study. The patients received T3 tablets or placebo for a three-month period, and switched to the opposite group for further three months in a blinded fashion. Heart function assessed with nuclear scans, ultrasound scans and blood measurements did not change. Hence, our study does not support that T3 treatment can be beneficial for patients with heart failure.
Featured Image
Why is it important?
T3 treatment does not seem to be a beneficial therapy.
Perspectives
This study does not support to persue treaments with T3 for patients with heart failure.
Dr Helena DOMINGUEZ VALL-LAMORA
Kobenhavns Universitet
Read the Original
This page is a summary of: Long-term L-Triiodothyronine (T3) treatment in stable systolic heart failure patients: a randomised, double-blind, cross-over, placebo-controlled intervention study, Clinical Endocrinology, December 2014, Wiley,
DOI: 10.1111/cen.12648.
You can read the full text:
Contributors
The following have contributed to this page
